Patheon has been selected by SK Life Science, Inc., the US-based subsidiary of Korean SK Holdings, as its development services partner for two Central Nervous System (CNS) drug candidates. Patheon will provide formulation and analytical development services as well as clinical supplies for one of the CNS candidates in advanced clinical studies. Patheon will also provide development and clinical materials manufacturing services for another CNS candidate in Phase I trials.
   
"We are very pleased to have been selected by SK Life Science to develop these important new drug candidates, and we look forward to continuing to provide them with exceptional service on their development projects," said Wes Wheeler, president and chief executive officer of Patheon. "This agreement to develop SK Life Science's two innovative candidates for the treatment of CNS disorders expands upon our existing relationship with the company, having recently completed Phase I development and clinical materials manufacturing for their next generation pain drug candidate."
   
"Patheon produced quality clinical materials for the pain drug project within our timelines. As a result we were very comfortable with awarding Patheon these two additional key projects," said Dr. S. James Lee, vice president pharmaceutical development of SK Life Science.

News from our sister sites